Protocol Ledger

NCT05053152 · Phase II · ACTIVE NOT RECRUITING

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Interventional Phase II clinical trial protocol NCT05053152 sponsored by NRG Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-20 Enrollment: 194 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05053152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)194 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05053152
Protocol FieldVerified Registry Value
NCT IdentifierNCT05053152
Consolidated Lead SponsorNRG Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment194 participants (ESTIMATED)
Registered Start Date2022-04-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI